Inhibitors of IRAK4 activity

US9926330B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Michael D. Altman · Cambridge, US
• Jason D. Brubaker · Cambridge, US
• Matthew L. Childers · Medfield, US
• Anthony Donofrio · Cambridge, US
• Thierry O. Fischmann · Scotch Plains, US
• Craig R. Gibeau · Holliston, US
• Solomon D. Kattar · Arlington, US
• Charles A. Lesburg · Newton, US
• Jongwon Lim · Lexington, US
• John MacLean · Brookline, US
• Umar Faruk Mansoor · Framingham, US
• Alan B. Northrup · Reading, US
• John M. Sanders · Hatfield, US
• Graham F. Smith · Sudbury, US

Key dates

• Filing date: Sep 25, 2015
• Grant date: Mar 27, 2018
• Expiry date: Sep 25, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.